Navigation Links
Regenicin Appoints Renowned New York Dermatologist, Dr. Gervaise Gerstner to Scientific Advisory Board
Date:10/27/2010

NEW YORK, Oct. 27 /PRNewswire-FirstCall/ -- Regenicin, Inc. (OTC Bulletin Board: WDST), a development stage company focusing on next-generation tissue-engineered skin substitutes to restore the qualities of healthy human skin, announced today the appointment of Dr. Gervaise Gerstner to the company's Scientific Advisory Board. Dr. Gerstner is a board-certified dermatologist and Assistant Clinical Professor of Dermatology at Mount Sinai Hospital in New York.

Dr. Gerstner earned her M.D. from Mount Sinai Medical School in New York City and completed a dermatology residency at Mount Sinai Hospital, where she was chosen to serve as Chief Resident of Dermatology. She is an associate member of the American Academy of Dermatology and the American Academy of Dermatologic Surgeons, and is a member of both the Dermatology Foundation and the Skin Cancer Foundation.  

"Dr. Gerstner brings more than ten years of clinical dermatology experience to our board," says Randall McCoy, CEO of Regenicin. "We are certain she will play a pivotal role in guiding the development of new applications, markets and technologies for the treatment of skin."

Dr. Gerstner, who is one of the world's first doctors trained in the highly advanced Fraxel laser, has conducted research on a wide range of topics from chemical peels to melanoma. Her work has been published in leading dermatologic journals and she served as book editor for Clinics in Dermatology. She is also regularly featured in national and regional media including W Magazine, Harper's Bazaar, Allure, Glamour, Self, New York and Real Simple.

"I worked closely with burn patients in medical school and during my residency, and continue to do so in my current practice," says Dr. Gerstner. "I am delighted to be part of a company that is on the cutting-edge of making life-saving technologies available for the treatment chronic burns and wounds."

About Regenicin, Inc.

Regenicin, Inc. is a development stage biotechnology company. Regenicin is a publicly traded company, with headquarters in New York. Additional information can be found in the company's filings with the Securities and Exchange Commission located at www.sec.gov.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Regenicin, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Regenicin to Form Scientific Advisory Board
2. Regenicin Names Former U.S. Marine Corp Operations Officer, Christopher Hadsall, Chief Operating Officer
3. Former Fujifilm Medical Systems USA Executive John J. Weber Agrees to Join Regenicin™ as a Member of Its Board of Directors and Interim CFO
4. Regenicin Completes Acquisition of Worldwide Exclusive Know-How Technology License from Lonza Walkersville
5. Bacterin International Reconstitutes Its Board of Directors and Appoints Experienced Legal and Financial Professionals
6. Tengion Appoints Richard E. Kuntz, MD to its Board of Directors
7. caprotec bioanalytics GmbH Appoints Prof. Dr. Rainer Metternich as Managing Director, Chief Business Officer and Chief Operating Officer
8. Resverlogix Appoints Kenneth J. Zuerblis to Board of Directors
9. Generex Biotechnology Appoints Mark Fletcher as Interim President and CEO, and John P. Barratt as Chairman of the Board
10. EUCODIS Bioscience Appoints Two Industry Executives to Realigned Advisory Board
11. ONCOTHYREON APPOINTS JULIE M. EASTLAND AS CHIEF FINANCIAL OFFICER
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... , March 1, 2017  Trovagene, Inc. (NASDAQ: TROV), ... today that it will report financial results for the fourth ... 15, 2017. Trovagene,s senior management team will host ... p.m. Eastern Daylight Time (2:00 p.m. Pacific Daylight Time) to ... ...
(Date:3/1/2017)... SHANGHAI , March 1, 2017  Luxcel ... based Biotechnology Company and HD Biosciences Co., ... Research Organization (CRO), announced today that they have ... new assay technologies for preclinical drug safety services. ... Luxcel,s state-of-the-art assays and technologies for assessment of ...
(Date:3/1/2017)... Conn. (PRWEB) , ... March 01, 2017 , ... ... Group, Inc. will hold its annual technology show and open house, Southern Tech ... CNC machinery from Okuma, Tsugami, Hardinge Group and Chiron and perform live metal ...
(Date:2/28/2017)... ... February 28, 2017 , ... ... Inc. (Newark, DE) have formed a strategic partnership to develop and market ... renewable energy laboratories. These automated testing solutions will save analysis time and ...
Breaking Biology Technology:
(Date:2/6/2017)... -- According to Acuity Market Intelligence, ongoing concerns ... continue to embrace biometric and digital identification based ... Control (ABC) eGates and 1436 Automated Passport Control ... ports of entry across the globe. Deployments increased ... CAGR of 37%. APC Kiosks reached 75% growth ...
(Date:2/2/2017)... 2, 2017   TapImmune, Inc. (NASDAQ: ... specializing in the development of innovative peptide and ... cancer and metastatic disease, announced today it has ... of a second clinical lot of TPIV 200, ... alpha. The manufactured vaccine product will be used ...
(Date:2/1/2017)... Massachusetts , February 1, 2017 IDTechEx ... events on emerging technology, announces the availability of a new report, ... Continue Reading ... ... in industrial and collaborative robots. Source: IDTechEx Report "Sensors for Robotics: ...
Breaking Biology News(10 mins):